EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Latent effector T cells mediate immunotherapy responses in the bone marrow microenvironment

Niklas Kehl, Tim R Wagner, Simon Steiger, Tamara Boschert, Michael Kilian, Antonia Schach, Julius J Michel, Kane Foster, Gabrielle M Hernandez, Claudia Ctortecka, Anna D Metzler, Alanna Kirschner und 41 weitere

Cancer Cell · 2026

DOI: 10.1016/j.ccell.2026.07.011 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Cell, 2026. Verfasst von Niklas Kehl und 52 weiteren Autor:innen. Beteiligte Einrichtung: German Cancer Research Center (DKFZ), JRG Hematology and Immune Engineering, Heidelberg, Germany; German Cancer Consortium (DKTK), Core Center Heidel…. Hauptthemen laut MEDLINE: Multiple Myeloma, Tumor Microenvironment, Immunotherapy, Leukemia, Myeloid, Acute. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 113 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Deutsche Akademie der Naturforscher Leopoldina - Nationale Akademie der Wissenschaften, Else Kröner Fresenius Foundation, Bundesministerium für Forschung Technologie und Raumfahrt Informationstechnikzentrum Bund.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

T cell-mediated immune surveillance is critical for cancer control, yet its role in bone marrow malignancies remains poorly understood. Here, we integrate TCR profiling, HLA immunopeptidomics, and functional screening to characterize tumor-reactive T cells in the bone marrow of patients with multiple myeloma (MM) and acute myeloid leukemia (AML). These cells are transcriptionally defined by a conserved effector program distinct from the exhausted phenotype of tumor-reactive T cells in solid cancers. Immunopeptidomic profiling reveals a partially shared antigen landscape enriched for noncanonical peptides driving convergent TCR responses. We develop TFiT (tumor-reactive features in T cells), a transcriptional classifier that identifies these cells and stratifies immunotherapy, but not chemotherapy, response across independent MM and AML cohorts, supporting its specificity for T cell-mediated tumor control. These findings reveal a latent but activatable anti-tumor T cell compartment in bone marrow malignancies and provide a framework for engaging endogenous immunity in MM and AML.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Multiple MyelomaTumor MicroenvironmentImmunotherapyLeukemia, Myeloid, AcuteBone MarrowT-LymphocytesHumansReceptors, Antigen, T-CellT-Cell Exhaustion

Stichwörter der Autor:innen

TCR repertoireTFiTacute myeloid leukemiabispecific antibodiesbone marrow microenvironmentimmune biomarkerimmunopeptidomicsmultiple myelomanoncanonical antigenstumor-reactive T cells

Substanzen

Receptors, Antigen, T-Cell

Autor:innen und Institutionen

  • German Cancer Research Center (DKFZ), JRG Hematology and Immune Engineering, Heidelberg, Germany; German Cancer Consortium (DKTK), Core Center Heidelberg, Heidelberg, Germany; Heidelberg Institute for Stem Cell Technolo…
  • German Cancer Research Center (DKFZ), Division of Chromatin Networks, Heidelberg, Germany; BioQuant, Heidelberg, Germany.
  • German Cancer Consortium (DKTK), Core Center Heidelberg, Heidelberg, Germany; German Cancer Research Center (DKFZ), CCU Neuroimmunology and Brain Tumor Immunology, Heidelberg, Germany; Department of Neurology, Medical F…
  • Ann Romney Center for Neurologic Diseases, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
  • Department of Haematology, Cancer Institute, University College London, London, UK.
  • Broad Institute of MIT and Harvard, Cambridge, MA, USA.

Förderung

  • Deutsche Akademie der Naturforscher Leopoldina - Nationale Akademie der Wissenschaften
  • Else Kröner Fresenius Foundation
  • Bundesministerium für Forschung Technologie und Raumfahrt Informationstechnikzentrum Bund
  • Deutschen Konsortium für Translationale Krebsforschung
  • Dr. Miriam and Sheldon G. Adelson Medical Research Foundation
  • José Carreras Leukämie-Stiftung
  • Nationales Centrum für Tumorerkrankungen Heidelberg
  • National Cancer Institute

Zitieren

APA

Kehl, N., Wagner, T. R., Steiger, S., Boschert, T., Kilian, M., Schach, A., Michel, J. J., Foster, K., Hernandez, G. M., Ctortecka, C., Metzler, A. D., Kirschner, A., Van der Vreken, A., Humer, D., Onken, R., Cuntz, S., Zoller, J., Funk, C., Neunhäuser, S., …, & Friedrich, M. J. (2026). Latent effector T cells mediate immunotherapy responses in the bone marrow microenvironment. Cancer Cell. https://doi.org/10.1016/j.ccell.2026.07.011

Vancouver

Kehl N, Wagner TR, Steiger S, Boschert T, Kilian M, Schach A, et al. Latent effector T cells mediate immunotherapy responses in the bone marrow microenvironment. Cancer Cell. 2026. doi:10.1016/j.ccell.2026.07.011

BibTeX
@article{Kehl2026,
  author = {Kehl, Niklas and Wagner, Tim R and Steiger, Simon and Boschert, Tamara and Kilian, Michael and Schach, Antonia and Michel, Julius J and Foster, Kane and Hernandez, Gabrielle M and Ctortecka, Claudia and Metzler, Anna D and Kirschner, Alanna and Van der Vreken, Arne and Humer, Dominik and Onken, René and Cuntz, Sven and Zoller, Julian and Funk, Cornelius and Neunhäuser, Selina and Mönnig, Maximilian and Schönfelder, Bruno and Renders, Simon and Maldonado Torres, Claudia and Sester, Lilli S and Frenking, Jan H and Werner, Franziska and Osen, Wolfram and Lindner, Katharina and Sen, Ezgi and Schumacher, Sabrina and Galas-Filipowicz, Daria and Fitzsimons, Evie and Green, Edward W and Schmidt, Patrick and Lindner, John M and Uhrig, Sebastian and Bunse, Lukas and Chain, Benny and Goldschmidt, Hartmut and Weinhold, Niels and Fröhling, Stefan and Sauer, Tim and Raffel, Simon and Abelin, Jennifer G and Carr, Steven A and Yong, Kwee and Trumpp, Andreas and Müller-Tidow, Carsten and Rippe, Karsten and Raab, Marc S and Platten, Michael and Eichmüller, Stefan B and Friedrich, Mirco J},
  title = {Latent effector T cells mediate immunotherapy responses in the bone marrow microenvironment},
  journal = {Cancer Cell},
  year = {2026},
  doi = {10.1016/j.ccell.2026.07.011}
}
Kostenlos starten →